GMU’s Reverse-phase Protein Microarray Technology Included in I-SPY2 Breast Cancer Trial | GenomeWeb

This story originally ran on March 25.

By Tony Fong

A proteomic technology will be used to help discover and identify new biomarkers to evaluate five new investigational breast cancer drugs as part of one of the biggest screening trials for the disease.

Last week, the Biomarkers Consortium announced the launch of I-SPY2 for the screening and development of new drugs to treat high-risk, fast growing breast cancers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.